Warner Pharmaceuticals (688799.SH) announced that recently, the company participated in the national Chinese Patent Medicine unified procurement office...
According to an announcement from Warner Pharmaceuticals (688799.SH), the company has recently participated in the centralized procurement of the National Chinese Patent Medicine Procurement Alliance (referred to as the 'Procurement Office') organized by the Procurement Office, as well as the centralized procurement of medical drugs and devices led by Hebei Province for the JING-JIN-JI and Gan regions. The proposed winning bids for the company's Ginkgo Biloba Blade, Fosfomycin Amide, and Diclofenac Sodium Sustained-release Tablets were indicated in the notifications issued by the Procurement Office and the Hebei Provincial Medical Device Procurement Center.
During the procurement period of the centralized procurement of the National Chinese Patent Medicine Procurement Alliance (first batch expansion continuation) and the centralized volume-based procurement of Chemical Drugs led by Hebei Province for the JING-JIN-JI and Gan regions, medical institutions and designated pharmacies in the winning areas will prioritize the use of the awarded medicines and ensure the completion of the agreed procurement quantities. If the company signs and executes procurement contracts thereafter, it will be beneficial to improve the accessibility of the aforementioned products, promote the expansion of related products, and enhance the company's brand influence.
